Commercial plans for Ryoncil™ were presented at the 2020 Biotech Showcase being held in San Francisco, CA on Jan 15, 2020.
On this day MSB share price was A$2.30-2.40
At this time, Mesoblast Chief Executive Dr. Silviu Itescu said: “We begin 2020 with great excitement as we prepare for potential FDA approval and US launch of our lead product candidate Ryoncil™ in pediatric aGVHD, a potentially life-threatening complication of an allogeneic bone marrow transplant. The continued growth in revenues from royalties on sales in Japan of the related product TEMCELL® for aGVHD by our licensee provides important insight for our own US commercial plans. Together with our strategic partners, we are also looking forward to readouts of Phase 3 trials for our blockbuster product candidates in advanced chronic heart failure and chronic low back pain due to degenerative disc disease.”
6 months later MSB share price is A$3.90
And we still have all of the news quoted above to come plus COVID ARDS trial…..
- Forums
- ASX - By Stock
- MSB
- MSB Trading - 2020
MSB Trading - 2020, page-13831
-
- There are more pages in this discussion • 9,330 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
92.0¢ |
Change
0.005(0.55%) |
Mkt cap ! $1.044B |
Open | High | Low | Value | Volume |
92.0¢ | 92.5¢ | 92.0¢ | $44.70K | 48.58K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 11317 | 92.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
92.5¢ | 56955 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 38 | 0.960 |
4 | 2001 | 0.945 |
1 | 7 | 0.940 |
3 | 2849 | 0.935 |
1 | 81 | 0.925 |
Price($) | Vol. | No. |
---|---|---|
0.870 | 7508 | 2 |
0.890 | 32 | 1 |
0.895 | 811 | 2 |
0.915 | 1367 | 1 |
0.920 | 220 | 1 |
Last trade - 10.05am 11/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |